Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study
evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m. each week) on the
year-to-year changes in two annual measures-magnetization transfer imaging and
diffusion-weighted imaging in patients with either relapsing-remitting (RR) or
secondary-progressive (SP) multiple sclerosis (MS). One hundred fifty (150) patients with RR
and SP MS-followed at the Jacobs Neurological Institute, University at Buffalo, Buffalo
NY-who satisfy both inclusion and exclusion criteria will be included. They will be assessed
at baseline and at 12 months with MRI and clinical examinations.